What Is AOD-9604? Definition and What Research Reports

Plain definition

AOD-9604 is a laboratory-made peptide that copies a small piece of human growth hormone (hGH) — specifically the final stretch of amino acids near the hormone's C-terminus, sometimes called the "lipolytic domain." The idea behind it was straightforward: if one region of a large hormone appeared responsible for effects on fat tissue, a short synthetic version of just that region might reproduce those metabolic effects without carrying along the rest of the hormone's activity, such as promoting tissue growth or altering insulin sensitivity. AOD-9604 is that short version. It is an analogue or fragment, not growth hormone itself, and it has not been approved as a medicine for obesity or body composition in any major jurisdiction.

What AOD-9604 is in biochemical terms

Human growth hormone is a 191-amino-acid protein. Researchers investigating which parts of the molecule carried which activities focused on the C-terminal region, and AOD-9604 corresponds to a modified fragment of that region — commonly described in the literature as hGH fragment 177–191 with a tyrosine residue added at the N-terminus. Because it lacks the great majority of the parent hormone's sequence, it does not fold or bind the way full-length hGH does at the growth hormone receptor, which is the mechanistic rationale investigators gave for expecting a different activity profile.

The peptide's short length also matters for how it behaves analytically and in the body. Work published in Drug Testing and Analysis characterised the detection and in vitro metabolism of AOD9604, describing the metabolites the peptide generated in vitro and the analytical approaches used to identify the compound and its breakdown products — the kind of groundwork required before a peptide can be screened for in anti-doping or forensic contexts.

Naming and spelling

The compound appears in the literature and in informal writing under several forms: AOD9604 (no hyphen, the style used in most journal titles), AOD-9604, hGH fragment 177-191, and occasionally "AOD" alone. These refer to the same molecule. "AOD" is generally read as "anti-obesity drug," a development-era label rather than a regulatory classification — it describes the intended research direction, not an approval status.

What the published literature reports

Rodent metabolic studies

The earliest widely cited work sits in metabolic pharmacology. A study in Hormone Research presented metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone, examining whether the isolated domain reproduced metabolic actions attributed to the parent hormone. Researchers framed the question as one of separability: whether lipid-related activity could be obtained from a fragment.

A follow-up in Endocrinology compared the effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-adrenergic receptor knock-out mice. The study reported on chronic dosing in obese mice and used β3-adrenergic receptor knock-out animals to probe whether the peptide's effects on lipid metabolism depended on that receptor pathway — a design choice that speaks to mechanism rather than to any human application. These are animal studies; the species, the models used, and the route of administration all limit what can be inferred about people.

A joint-tissue model

Beyond metabolism, one line of investigation looked at cartilage. A study in Annals of Clinical and Laboratory Science examined the effect of intra-articular injection of AOD9604 with or without hyaluronic acid in a rabbit osteoarthritis model. Researchers delivered the peptide directly into the joint space, alone and in combination with hyaluronic acid, in surgically induced osteoarthritis in rabbits. This work is often cited informally as evidence that AOD-9604 "repairs joints"; the study itself was a preclinical animal model with the limitations that implies, and it did not establish clinical outcomes in humans.

Analytical and anti-doping literature

The 2015 detection and in vitro metabolism paper represents a distinct category of research: not asking what a peptide does, but how it can be found. Papers of this kind exist because a compound circulates outside approved medical channels and testing bodies need methods to identify it. Their presence in the literature is a signal about the compound's regulatory and sporting status, not about efficacy.

How the term is used — and where it is misused

The most common misuse online is treating rodent findings as though they were human results. The metabolic studies above were conducted in mice, including genetically modified strains chosen to test a mechanism. Nothing in a knock-out mouse model transfers automatically to human physiology, and the published record cited here does not contain human efficacy trials.

A second recurring error is category confusion. AOD-9604 is sometimes grouped with growth hormone secretagogues — peptides that stimulate the pituitary to release endogenous growth hormone. That is a different mechanism entirely. AOD-9604 is a fragment of the hormone, not a releasing agent.

Related terms

• Human growth hormone (hGH / somatropin) — the 191-amino-acid parent protein from which the AOD-9604 sequence is derived.
• hGH fragment 177-191 — the sequence descriptor most often used interchangeably with AOD-9604.
• Lipolysis — the breakdown of stored triglycerides into fatty acids and glycerol; the process the "lipolytic domain" naming refers to.
• β3-adrenergic receptor — a receptor involved in fat tissue metabolism, used as a knock-out target in the 2001 Endocrinology study (PMID 11713213).
• Intra-articular — administration directly into a joint space, the route used in the rabbit osteoarthritis study (PMID 26275694).
• In vitro metabolism — laboratory study of how a compound is chemically broken down outside a living organism, the subject of the 2015 detection paper (PMID 25208511).
• Research use only (RUO) — a labelling category for materials sold for laboratory work and not for human administration.

Regulatory status in brief

AOD-9604 has no marketing approval as a drug for weight management or joint disease. In some jurisdictions it has been evaluated in other regulatory categories, and it has appeared in anti-doping discussions — the existence of dedicated detection methodology in the analytical literature reflects that interest. Peptides in this position are typically distributed as research chemicals rather than as pharmaceuticals, which means no regulator has reviewed manufacturing quality, purity, or safety for human use. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision or before considering any substance.

What the evidence base does and does not cover

Summarising the verified literature: researchers have reported on the peptide's effects on lipid metabolism in obese and knock-out mice, on intra-articular delivery in a rabbit osteoarthritis model, and on how the compound and its metabolites can be detected analytically. That is the shape of the record — mechanistic and preclinical. Absent from this set are large human trials, long-term safety follow-up, and comparative effectiveness data against established treatments. Readers encountering confident claims about human fat loss or joint regeneration should note the distance between those claims and what the studies above actually measured.

References

• Detection and in vitro metabolism of AOD9604 (Drug Testing and Analysis, 2015)
• Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model (Annals of Clinical and Laboratory Science, 2015)
• The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice (Endocrinology, 2001)
• Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone (Hormone Research, 2000)